First published February 21, 2022.
Altos Labs is a biotechnology company that came out of stealth on 19 January 2022 with $3 billion in funding, reportedly the largest launch of any biotech start-up. Its goal is to understand how cells can be "rejuvenated" and to use that knowledge to treat disease and age-related decline. Jeff Bezos was widely reported to be one of its backers, which led to headlines about the Amazon founder funding a quest for immortality.
The reality is more interesting and more cautious. Altos is a research company, the $3 billion did not come from Bezos alone, and no Altos treatment has yet been approved for use in people.
Who is behind Altos Labs
The idea for the company came from Richard (Rick) Klausner, a cell biologist and former director of the US National Cancer Institute, who co-founded it with Hans Bishop, a biotech executive. The name comes from Los Altos in California. A scientific meeting in October 2020, co-hosted by the tech investor Yuri Milner, helped shape the plan.
Altos did not publish a list of its investors, describing them only as renowned company builders and investors. News reports named Milner and Bezos as early backers, along with Robert Nelsen of ARCH Venture Partners. So the popular headline that Bezos "put $3 billion" into the company is not accurate: the total came from several investors, and Bezos's own share was never disclosed.
Another small correction: by early 2022 Bezos was no longer the world's richest person. Elon Musk first overtook him in January 2021, and by early 2022 Musk was ranked first.
The scientists it recruited
Altos attracted an unusually star-studded team:
- Hal Barron, previously chief scientific officer and president of research and development at the drug company GSK, became chief executive and co-chair.
- Rick Klausner became chief scientist, and Hans Bishop president.
- Shinya Yamanaka, who shared the 2012 Nobel Prize in Physiology or Medicine for discovering that adult cells can be reprogrammed into stem cells, joined as an unpaid senior scientific adviser overseeing work in Japan.
- Jennifer Doudna, co-winner of the 2020 Nobel Prize in Chemistry for the CRISPR gene-editing method, joined the board of directors, rather than working as a staff scientist.
- Research institutes were led by Peter Walter in the San Francisco Bay Area, Juan Carlos Izpisua Belmonte in San Diego and Wolf Reik in Cambridge, UK.
The company planned sites in the Bay Area, San Diego and Cambridge, with significant collaborations in Japan. It has since grown to several hundred employees, and reports at launch suggested it was offering senior researchers salaries far above typical academic pay.
The science: cellular rejuvenation programming
The work builds on a discovery Yamanaka made in 2006. His team showed that switching on four genes, now called the Yamanaka factors (Oct4, Sox2, Klf4 and c-Myc), could turn ordinary mouse skin cells into induced pluripotent stem cells, which behave like embryonic cells. A year later the same approach worked in human cells.
Full reprogramming wipes a cell's identity, which is not what anyone wants inside a living body. Researchers have therefore explored "partial reprogramming": exposing cells to the factors briefly, so that they shed some markers of ageing, such as changes in the chemical tags on DNA known as the epigenetic clock, while keeping their identity as skin, muscle or nerve cells.
At launch, Barron said the work of Yamanaka and others showed that cells "have the ability to rejuvenate, resetting their epigenetic clocks." Altos's stated aim is to learn how that happens and to turn it into medicines that could reverse disease for patients of any age.
The open questions
Studies in laboratory mice have reported that partial reprogramming can reverse some signs of ageing, but the safety challenges are serious. Cells pushed too far can form tumours called teratomas, and some of the factors, especially c-Myc, are linked to cancer. Getting the dose, timing and target tissue right in people is a problem no one has yet solved.
Rejuvenation versus immortality
Altos itself has avoided talk of living forever. Hans Bishop has said that the aim is to extend healthspan, the years lived in good health, and that any increase in lifespan would be an accidental consequence. That is a long way from the "fountain of youth" framing in many headlines.
Some common myths about the company are worth correcting:
- Myth: Bezos hired scientists to make him immortal. He was reported to be one investor among several, and the company describes its work as treating disease.
- Myth: Altos has a youth treatment. As of 2026, it has no approved therapy and has said little publicly about clinical trials.
- Myth: rejuvenation would end diseases like dementia and cancer. Researchers hope that understanding cell ageing could help with age-related diseases, but this is a hypothesis, not a demonstrated result.
Anyone tempted by products marketed as cellular rejuvenation or anti-ageing therapies should be cautious; none of the reprogramming approaches studied by Altos is available as a treatment, and it is best to talk to a doctor before trying any supplement or clinic promising to reverse ageing.
What has happened since 2022
Altos has remained relatively secretive, focusing on basic research rather than a near-term product. In May 2025 it made a small acquisition, buying a small start-up called Dorian Therapeutics that was also working on reversing aspects of ageing. The terms were not disclosed.
The company is part of a wider wave of longevity ventures backed by wealthy technology investors, including Google-funded Calico, which shows how much private money is now flowing into the biology of ageing. That money buys time and talent, but not certainty. Basic research of this kind can take many years to produce a medicine, if it does at all.
Why it still matters
Even without a product, Altos is significant. It brought together leading scientists from reprogramming, epigenetics and cell biology under one roof with funding that few university labs could match, and it gave the idea of treating ageing as a biological process a new level of credibility.
The best way to read news about it is the same as for any early-stage science: separate the size of the investment from evidence that something works, look for peer-reviewed results, and be wary of headlines promising immortality. If Altos does succeed, the first benefits are likely to be treatments for specific diseases, not an end to growing old.
Sources: Altos Labs (Wikipedia); GEN, 19 January 2022: Altos Labs launches with $3B; Altos Labs press release, January 2022; Induced pluripotent stem cell (Wikipedia); Endpoints News, 21 May 2025: Altos Labs buys Dorian Therapeutics; Al Jazeera, 7 January 2021: Musk overtakes Bezos; Futurism, 2022.
COMMENTS